

# PRODUCT INFORMATION



## Atazanavir

Item No. 11733

**CAS Registry No.:** 198904-31-3  
**Formal Name:** 3S,12S-bis(1,1-dimethylethyl)-8S-hydroxy-4,11-dioxo-9S-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-2,5,6,10,13-pentaazatetradecanedioic acid, 1,14-dimethyl ester

**Synonyms:** BMS 232632, CGP 73547

**MF:** C<sub>38</sub>H<sub>52</sub>N<sub>6</sub>O<sub>7</sub>

**FW:** 704.9


**Purity:** ≥95%

**UV/Vis.:** λ<sub>max</sub>: 251, 280 nm

**Supplied as:** A crystalline solid

**Storage:** -20°C

**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Atazanavir is supplied as a crystalline solid. A stock solution may be made by dissolving the atazanavir in the solvent of choice. Atazanavir is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of atazanavir in these solvents is approximately 2, 16, and 25 mg/ml, respectively.

Atazanavir is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, atazanavir should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Atazanavir has a solubility of approximately 0.1 mg/ml in a 1:8 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

Atazanavir is an azapeptide inhibitor of HIV-1 protease ( $K_i = 2.66$  nM).<sup>1</sup> It has antiviral activity against a variety of HIV-1 strains in several cell types with  $EC_{50}$  values ranging from 2.62 to 5.28 nM. Atazanavir exhibits a minor synergistic effect when used in combination with the reverse transcriptase inhibitor zidovudine (Item No. 15492) in HIV-1-infected human peripheral blood mononuclear cells (PBMCs) and an additive effect when used in combination with several additional reverse transcriptase or HIV-1 protease inhibitors. Atazanavir also inhibits UDP-glucuronyltransferase 1A1 (UGT1A1), which is involved in bilirubin clearance.<sup>2</sup> Formulations containing atazanavir have been used in combination therapy for the treatment of HIV-1 infection.

### References

1. Robinson, B.S., Riccardi, K.A., Gong, Y.-F., *et al.* BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. *Antimicrob. Agents Chemother.* **44(8)**, 2093-2099 (2000).
3. Michaud, V., Bar-Magen, T., Turgeon, J., *et al.* The dual role of pharmacogenetics in HIV treatment: Mutations and polymorphisms regulating antiretroviral drug resistance and disposition. *Pharmacol. Rev.* **64(3)**, 803-833 (2012).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/14/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM